Future For Spexis Looks Far From Secure
Swiss Biotech Launched End of 2021
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
You may also be interested in...
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.